Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome
Abstract Background Dystonia is a key symptom in corticobasal syndrome (CBS), and upper limb dystonia is the most common phenotype. Dystonia‐associated pain is frequently reported and can be disabling, with poor benefit from oral treatments. Aims of the Study To investigate the role of botulinum tox...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-06-01
|
| Series: | Brain and Behavior |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/brb3.1182 |
| _version_ | 1818042196072333312 |
|---|---|
| author | Elisa Unti Sonia Mazzucchi Rosanna Calabrese Giovanni Palermo Eleonora Del Prete Ubaldo Bonuccelli Roberto Ceravolo |
| author_facet | Elisa Unti Sonia Mazzucchi Rosanna Calabrese Giovanni Palermo Eleonora Del Prete Ubaldo Bonuccelli Roberto Ceravolo |
| author_sort | Elisa Unti |
| collection | DOAJ |
| description | Abstract Background Dystonia is a key symptom in corticobasal syndrome (CBS), and upper limb dystonia is the most common phenotype. Dystonia‐associated pain is frequently reported and can be disabling, with poor benefit from oral treatments. Aims of the Study To investigate the role of botulinum toxin A (BoTNA) in the treatment of dystonia and associated pain in CBS. Methods Ten consecutive patients with a clinical diagnosis of probable CBS and dystonia with/without associated pain were treated with BoTNA every 3 months. Treatment efficacy was assessed during the first follow‐up visit, three months after the first injection, by means of caregiver impression (CI), evaluation of muscle tone with the Ashworth scale (AS), severity of pain measured with the visual analog scale (VAS). Results Nine subjects underwent at least three treatments, four patients discontinued for progressive reduction in efficacy or disease progression, five patients are ongoing with good response, and one completed the 10th treatment. No local or systemic side effects were reported, and levodopa equivalent daily dose remained unchanged in most cases during the observational period. Significant improvement of AS was recorded (from 2.9 ± 0.7 to 2.0 ± 0.5, p = 0.003). CI ranged from mild to moderate benefit. All patients reported efficacy on pain, with a significant reduction of VAS score (from 7.7 ± 1.7 to 1.7 ± 0.7 in the Pain group, p = 0.016). Conclusions Our study confirms safety, efficacy, and tolerability of BoTNA in the treatment of dystonia associated with CBS. Local treatment should be considered as a valid alternative to oral treatment modulation mainly in the presence of associated pain. |
| first_indexed | 2024-12-10T08:42:28Z |
| format | Article |
| id | doaj.art-35863b3b524c4dfaabfb569e77ed6624 |
| institution | Directory Open Access Journal |
| issn | 2162-3279 |
| language | English |
| last_indexed | 2024-12-10T08:42:28Z |
| publishDate | 2019-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Brain and Behavior |
| spelling | doaj.art-35863b3b524c4dfaabfb569e77ed66242022-12-22T01:55:49ZengWileyBrain and Behavior2162-32792019-06-0196n/an/a10.1002/brb3.1182Botulinum toxin for the treatment of dystonia and pain in corticobasal syndromeElisa Unti0Sonia Mazzucchi1Rosanna Calabrese2Giovanni Palermo3Eleonora Del Prete4Ubaldo Bonuccelli5Roberto Ceravolo6Neurology Unit Ospedale Apuano Massa ItalyNeurology Unit, Department of Medical Specialties Azienda Ospedaliero Universitaria Pisana Pisa ItalyNeurology Unit, Department of Medical Specialties Azienda Ospedaliero Universitaria Pisana Pisa ItalyNeurology Unit, Department of Clinical and Experimental Medicine University of Pisa Pisa ItalyNeurology Unit, Department of Clinical and Experimental Medicine University of Pisa Pisa ItalyNeurology Unit, Department of Clinical and Experimental Medicine University of Pisa Pisa ItalyNeurology Unit, Department of Clinical and Experimental Medicine University of Pisa Pisa ItalyAbstract Background Dystonia is a key symptom in corticobasal syndrome (CBS), and upper limb dystonia is the most common phenotype. Dystonia‐associated pain is frequently reported and can be disabling, with poor benefit from oral treatments. Aims of the Study To investigate the role of botulinum toxin A (BoTNA) in the treatment of dystonia and associated pain in CBS. Methods Ten consecutive patients with a clinical diagnosis of probable CBS and dystonia with/without associated pain were treated with BoTNA every 3 months. Treatment efficacy was assessed during the first follow‐up visit, three months after the first injection, by means of caregiver impression (CI), evaluation of muscle tone with the Ashworth scale (AS), severity of pain measured with the visual analog scale (VAS). Results Nine subjects underwent at least three treatments, four patients discontinued for progressive reduction in efficacy or disease progression, five patients are ongoing with good response, and one completed the 10th treatment. No local or systemic side effects were reported, and levodopa equivalent daily dose remained unchanged in most cases during the observational period. Significant improvement of AS was recorded (from 2.9 ± 0.7 to 2.0 ± 0.5, p = 0.003). CI ranged from mild to moderate benefit. All patients reported efficacy on pain, with a significant reduction of VAS score (from 7.7 ± 1.7 to 1.7 ± 0.7 in the Pain group, p = 0.016). Conclusions Our study confirms safety, efficacy, and tolerability of BoTNA in the treatment of dystonia associated with CBS. Local treatment should be considered as a valid alternative to oral treatment modulation mainly in the presence of associated pain.https://doi.org/10.1002/brb3.1182botulinum toxincorticobasal syndromedystoniapain |
| spellingShingle | Elisa Unti Sonia Mazzucchi Rosanna Calabrese Giovanni Palermo Eleonora Del Prete Ubaldo Bonuccelli Roberto Ceravolo Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome Brain and Behavior botulinum toxin corticobasal syndrome dystonia pain |
| title | Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome |
| title_full | Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome |
| title_fullStr | Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome |
| title_full_unstemmed | Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome |
| title_short | Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome |
| title_sort | botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome |
| topic | botulinum toxin corticobasal syndrome dystonia pain |
| url | https://doi.org/10.1002/brb3.1182 |
| work_keys_str_mv | AT elisaunti botulinumtoxinforthetreatmentofdystoniaandpainincorticobasalsyndrome AT soniamazzucchi botulinumtoxinforthetreatmentofdystoniaandpainincorticobasalsyndrome AT rosannacalabrese botulinumtoxinforthetreatmentofdystoniaandpainincorticobasalsyndrome AT giovannipalermo botulinumtoxinforthetreatmentofdystoniaandpainincorticobasalsyndrome AT eleonoradelprete botulinumtoxinforthetreatmentofdystoniaandpainincorticobasalsyndrome AT ubaldobonuccelli botulinumtoxinforthetreatmentofdystoniaandpainincorticobasalsyndrome AT robertoceravolo botulinumtoxinforthetreatmentofdystoniaandpainincorticobasalsyndrome |